IGF1R and sarcoma: Twenty-nine patients with Ewing’s sarcoma and a heterogeneous group of other sarcoma subtypes were treated with single agent figitumumab (CP-751, 871, Pfizer, IgG2 monoclonal antibody to IGF-1R) using a dose of 20 mg/kg every 3 weeks.